Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 559


2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors.

Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, Fuchs J, Schmidt M, Prasad V, Krug B, Timmermann B, Leuschner I, Fischer M, Langer T, Astrahantseff K, Berthold F, Lode H, Eggert A.

Klin Padiatr. 2017 May;229(3):147-167. doi: 10.1055/s-0043-103086. Epub 2017 May 30.


Corrigendum: Antibody-antigen kinetics constrain intracellular humoral immunity.

Bottermann M, Lode HE, Watkinson RE, Foss S, Sandlie I, Andersen JT, James LC.

Sci Rep. 2017 Apr 6;7:45418. doi: 10.1038/srep45418. No abstract available.


Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.

Tivnan A, Heilinger T, Ramsey JM, O'Connor G, Pokorny JL, Sarkaria JN, Stringer BW, Day BW, Boyd AW, Kim EL, Lode HN, Cryan SA, Prehn JH.

Oncotarget. 2017 Mar 7;8(10):16605-16620. doi: 10.18632/oncotarget.15073.


Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.

Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Jüttner M, Ehlert K, Kietz S, Müller I, Lode HN.

Oncoimmunology. 2016 Sep 26;5(11):e1235108. doi: 10.1080/2162402X.2016.1235108. eCollection 2016.


Antibody-antigen kinetics constrain intracellular humoral immunity.

Bottermann M, Lode HE, Watkinson RE, Foss S, Sandlie I, Andersen JT, James LC.

Sci Rep. 2016 Nov 24;6:37457. doi: 10.1038/srep37457.


GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier's gangrene and severe septic shock in an adolescent.

Winkler A, Kietz S, Bahlmann H, Jafarzade G, Lode HN, Heckmann M.

Clin Case Rep. 2016 Jul 20;4(8):816-9. doi: 10.1002/ccr3.616. eCollection 2016 Aug.


The impact of socioeconomic factors on the efficiency of voluntary toxoplasmosis screening during pregnancy: a population-based study.

Lange AE, Thyrian JR, Wetzka S, Flessa S, Hoffmann W, Zygmunt M, Fusch C, Lode HN, Heckmann M.

BMC Pregnancy Childbirth. 2016 Jul 29;16(1):197. doi: 10.1186/s12884-016-0966-0.


MYCN-targeting vaccines and immunotherapeutics.

Schramm A, Lode H.

Hum Vaccin Immunother. 2016 Sep;12(9):2257-8. doi: 10.1080/21645515.2016.1171430. Epub 2016 Apr 20.


Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.

Eger C, Siebert N, Seidel D, Zumpe M, Jüttner M, Brandt S, Müller HP, Lode HN.

PLoS One. 2016 Mar 11;11(3):e0150479. doi: 10.1371/journal.pone.0150479. eCollection 2016.


Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.

Siebert N, Eger C, Seidel D, Jüttner M, Zumpe M, Wegner D, Kietz S, Ehlert K, Veal GJ, Siegmund W, Weiss M, Loibner H, Ladenstein R, Lode HN.

MAbs. 2016;8(3):604-16. doi: 10.1080/19420862.2015.1130196. Epub 2016 Jan 19.


Targeting of heme oxygenase-1 as a novel immune regulator of neuroblastoma.

Fest S, Soldati R, Christiansen NM, Zenclussen ML, Kilz J, Berger E, Starke S, Lode HN, Engel C, Zenclussen AC, Christiansen H.

Int J Cancer. 2016 Apr 15;138(8):2030-42. doi: 10.1002/ijc.29933. Epub 2015 Dec 12.


[Vaccinations in respiratory medicine].

Lode HM, Stahlmann R.

HNO. 2015 Sep;63(9):649-59; quiz 659-60. doi: 10.1007/s00106-015-0058-x. German.


Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.

Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group.

Lancet. 2015 Sep 19;386(9999):1156-64. doi: 10.1016/S0140-6736(14)62395-3. Epub 2015 Jul 9.


Mutational dynamics between primary and relapse neuroblastomas.

Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH.

Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29.


Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.

Stermann A, Huebener N, Seidel D, Fest S, Eschenburg G, Stauder M, Schramm A, Eggert A, Lode HN.

Cancer Immunol Immunother. 2015 Oct;64(10):1215-27. doi: 10.1007/s00262-015-1733-1. Epub 2015 Jun 16.


Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, Lode HN.

Cancer Immunol Immunother. 2015 May;64(5):621-34. doi: 10.1007/s00262-015-1669-5. Epub 2015 Feb 25.


[Pharmacokinetics of antibiotics in obese and critical care patients].

Stahlmann R, Lode H.

Dtsch Med Wochenschr. 2015 Feb;140(4):271-6. doi: 10.1055/s-0041-100443. Epub 2015 Feb 19. Review. German.


Febrile ulceronecrotic Mucha-Habermann disease following suspected hemorrhagic chickenpox infection in a 20-month-old boy.

Lode HN, Döring P, Lauenstein P, Hoeger P, Dombrowski F, Bruns R.

Infection. 2015 Oct;43(5):583-8. doi: 10.1007/s15010-015-0726-5. Epub 2015 Jan 28.


The clinical positioning of telavancin in Europe.

Masterton R, Cornaglia G, Courvalin P, Lode HM, Rello J, Torres A.

Int J Antimicrob Agents. 2015 Mar;45(3):213-20. doi: 10.1016/j.ijantimicag.2014.12.006. Epub 2014 Dec 24. Review.


Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.

Siebert N, Seidel D, Eger C, Jüttner M, Lode HN.

PLoS One. 2014 Sep 16;9(9):e107692. doi: 10.1371/journal.pone.0107692. eCollection 2014.

Supplemental Content

Loading ...
Support Center